No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma

BACKGROUND: Sorafenib is a standard therapy for patients with advanced hepatocellular carcinoma (HCC). However, no predictive biomarkers of sorafenib efficacy have been discovered. Herein, we investigated the impact of body composition, such as skeletal muscle and visceral fat, on the prognosis of a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Liver Cancer
Autors principals: Saeki, Issei, Yamasaki, Takahiro, Maeda, Masaki, Kawano, Reo, Hisanaga, Takuro, Iwamoto, Takuya, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2018
Matèries:
Original Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6249591/
https://ncbi.nlm.nih.gov/pubmed/30488024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000487858
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars